CDR Update — Issue 61
October 9, 2009
In This Issue
CEDAC Recommendations — July 1, 2009 to September 30, 2009
The following CEDAC formulary listing recommendations were posted on the CADTH website between July 1, 2009 and September 30, 2009.
|
Table 1: CEDAC Recommendations |
||||
|
Drug Name |
Submission Type |
Indication (Condition) |
Recommendation Release Date |
CEDAC Final Recommendation and Reasons for Recommendation |
|
Pregabalin |
Resubmission #1 |
Neuropathic pain associated with diabetic peripheral neuropathy |
2009-09-23 |
|
|
Desvenlafaxine succinate |
Initial |
Major depressive disorder |
2009-09-23 |
|
|
Insulin detemir |
New Indication |
Diabetes mellitus type 1, pediatrics |
2009-08-19 |
|
|
Insulin detemir |
Resubmission #2 |
Diabetes mellitus, type 1 or type 2, adults |
2009-08-19 |
|
|
Levodopa / carbidopa |
Initial |
Parkinson disease |
2009-07-22 |
|
|
Teriparatide (rDNA origin) injection |
New Indication |
Osteoporosis (glucocorticoid induced) |
2009-07-22 |
|
CEDAC = Canadian Expert Drug Advisory Committee.
Personnel News
Tim Veregin will be leaving CADTH as of October 8, 2009 to pursue other opportunities. CADTH sincerely thanks Tim for his contributions to CDR in both the role of Manager of Submissions and as Manager of Reviews. Tim will be greatly missed.
As a result of Tim’s departure, industry and those filing submissions should contact Trinh Luong, Director, Submissions and Operations, for all CDR submission-related inquiries. Trinh can be contacted by email at trinhl@cadth.ca or by telephone at 613-226-2553, ext. 1492. Trinh joined CADTH on September 28. We are pleased to welcome her to the CDR team.